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In some patients severe spasticity of cerebral or spinal origin cannot be 
treated successfully with conventional oral medication or physical modalities. 
Intrathecal baclofen therapy with implanted pump has represented effective 
treatment from mid-80’s. Baclofen (Lioresal) is a muscle relaxant and a potent 
GABA agonist that acts via GABAb receptors at the posterior columns of spinal 
cord level, to inhibit the release of excitatory neurotransmitters by inhibiting 
calcium ions influx into presynaptic terminals. This direct binding on spinal 
cord receptors leads to higher efficiency compared to peroral therapy in which 
baclofen does not pass the brain-blood barrier. The article overviews indications 
and contraindications for intrathecal baclofen therapy, selection and preparation 
of patients for surgery, the surgical procedure of pump implantation, long term 
follow-up with pump refill procedure and possible complications of intratecal 
baclofen therapy. The experiences of the Center for spasticity treatment at the 
University Rehabilitation Institute in Ljubljana are described.
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kao funkcijsko liječenje teške spastičnosti 
Sažetak
U nekih bolesnika teška spastičnost, moždanog ili spinalnog porijekla, ne može 
se uspješno liječiti konvencionalnim, oralnim lijekovima ili fizikalnom terapijom. 
Intratekalna terapija baklofenom s implantiranom pumpom predstavlja učinkovit 
tretman još od sredine 80-ih godina prošlog stoljeća. Baklofen (Lioresal) mišićni 
je relaksant i moćan agonist GABA receptora koji djeluje preko GABAb receptora 
u stražnjim rogovima leđne moždine, inhibirajući oslobađanje ekscitatornih neu-
rotransmitera inhibicijom dotoka kalcijevih iona u presinaptički terminal. Ovo izrav-
no vezivanje na receptore leđne moždine dovodi do veće učinkovitosti u odnosu 
na peroralnu terapiju, u kojoj baklofen ne prolazi krvno-moždanu barijeru. Članak 
govori o indikacijama i kontraindikacijama za intratekalnu terapiju baklofenom, 
odabiru i pripremi bolesnika za operaciju, kirurškom postupku implantacije pumpe, 
dugoročnom praćenju s postupkom punjenja pumpe te o mogućim komplikacijama 
intratekalne baklofenske terapije. Opisana su iskustva Jedinice za liječenje spastici-
teta na Sveučilišnom Rehabilitacijskom Institutu Soča u Ljubljani.




Spasticity as a clinical sign was excellently described by the editorial article in 
British Medical Journal in 1973: Spasticity is a condition in which the stretch 
reflexes that are normally latent become obvious. The tendon reflexes have 
a lower threshold to tap, the response of the tapped muscle is increased and 
usually the muscles beside tapped also respond. Tonic stretch reflexes are 
affected the same way (1).
The formal definition of Lance et al. was in use from 1980 (2): A motor disorder 
characterized by a velocity dependent increase in tonic stretch reflex (muscle 
tone) with exaggerated (phasic) tendon jerks resulting from hyper excitability 
of the stretch reflex as one component of an upper motor neuron syndrome.
In 2004, an “EU-SPASM (Support Programme for Assembly of database for 
Spasticity Measurement 2002-2004)” group published the latest definition 
of spasticity (3): “Disordered sensori-motor control, resulting from an upper 
motor neuron lesion, presenting as intermittent or sustained involuntary 
activation of muscles”.
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Nevertheless, “spasticity” as a clinical sign should be distinguished from 
“spasticity” as one factor only among many that contributes to motor 
dysfunction in the presence of the upper motor neuron syndrome (4).
Spasticity as a clinical problem has nevertheless an important influence 
on patients’ ability and quality of life, and therefore represents a major 
rehabilitation problem and should be a focus of therapy for P&R medicine 
specialists. Spasticity is an expensive, often undertreated condition, with 
heavy economic burden for the patients, caregivers and society and a cause of 
disability due to decreased mobility, weakness, and fatigue (5, 6). Spasticity 
results in increased dependence on family and institutional caregivers for 
activities of daily living. It consequently ends in costly complications such as 
joint contractures and pressure sores with decreased quality of life (7, 8). 
On the other hand, patients are often undertreated due to side effects of 
oral antispastic medication. Spasticity treatment should be initiated when: 
Spasticity interferes with functioning, positioning, comfort and care, it is not 
useful (e.g. during transfers) and when treatment is expected to provide 
meaningful improvement.
Intrathecal Drug Delivery of Baclofen
with Programmable Pump
Baclofen is a first line drug in the treatment of spasticity. It is structurally 
similar to the neurotransmitter GABA and it is a muscle relaxant and a potent 
GABA agonist that acts via GABAb receptors at the posterior columns of spinal 
cord level, to inhibit the release of excitatory neurotransmitters by inhibiting 
Ca influx into presynaptic terminals (9). What is most important is that it 
does not pass the blood-brain barrier, therefore the majority of oral intake of 
baclofen remains in the serum and is present in the spinal fluid only in traces. 
General indications for treatment
with intrathecal baclofen pump
Spasticity of cerebral or spinal origin, which is a cause of restriction: 
• ambulation/transfer/seating, 
• daily activities & care, 
• rehabilitation interventions & progress, 
• daily rest or sleeping or 
• causes pain / discomfort and 
• is a potential factor for late complications (pressure ulcers, contractures…).
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Typical conditions suitable for intrathecal baclofen therapy are: spinal cord 
injury, multiple sclerosis, traumatic and hypoxic brain injury, stroke, cerebral 
palsy and hereditary spastic paraparesis.
Pump implantation is contraindicated with severe internistic diseases, acute 
or chronic infections, severe psychiatric disturbances and resistant epilepsy. 
The pump cannot be implanted in asthenic children with body weight less than 
10 kilograms. When tissue and tendon contractures are already developed, 
intrathecal baclofen would not improve tone nor range of joint motion 
or function. Implanted electronic devices (i.e. pacemaker) and frequent 
generalized epileptic seizures are relative contraindications (precautions) for 
implantation.
Prior to implantation a test of intrathecal baclofen is performed by repeated 
boluses via catheter or by temporary continuous infusion with an external 
pump. Lumbar puncture at the L3-L4 interspace is performed and then a bolus 
of baclofen is given every 24 hrs via epidural catheter in the range 25 – 100 
µg in adults and 10 – 50 µg in children. Alternatively, an external pump can 
be attached to the catheter and this can simulate the real situation with an 
implanted pump, which is particularly useful in ambulatory and high-functioning 
patients. Positive test is confirmed, when a reduction of spasticity is observed 
for at least one grade on the Modified Ashwort scale in key muscles, without 
a decrease in functional status, preferably an increase. In the period of 2, 4 
& 6 (or 8) hours after bolus, the following parameters are recommended to 
observe: muscle tone in target muscles with (Modified) Ashwort scale, adductor 
tone rating in hip adductors and spasm frequency, clonus rating, pain scale 
(VAS 0 – 100), Barry-Albright dystonia scale, active & passive ROM in target 
joints (degrees), muscle action – MRC scale.
After consideration of indications and after a positive baclofen test, the patient is 
scheduled for the surgical procedure. The procedure is performed under general 
anaesthesia and usually lasts 60 minutes. It consists of placing the catheter 
intrathecally, forming a subcutaneous pocket for the pump left suprainguinally 
and connecting the lumbar catheter via subcutaneous tunelling with the pump. 
The pump is filled with the baclofen solution just before implantation and the 
pump itself is programmed and starts just after the surgical procedure. After 
the surgery patient stays at the neurosurgery department for a short time and 
is then transferred to a rehabilitation department for baclofen dose adjustment 
and post-implantation management. If there is no external spinal fluid leakage 
and wound complications, gradual mobilization (72 hrs) is promoted to the 
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wheelchair use or walking. In the meantime, the oral spasmolytic drugs are 
reduced and the intrathecal baclofen daily dose is adapted with a telemetric 
programmer in case the pump is programmable. Post-implantation rehabilitation 
management consists of gradual mobilisation, stretching, relearning the 
physical activities after the altered situation, occupational therapy, functional 
re-training and adaptation of equipment such as wheelchair.
After setting the optimal daily dose of intrathecal baclofen, the patient is 
discharged home and scheduled for regular pump reservoir refill. Pump refill 
is done on an outpatient basis with the specially educated rehabilitation team. 
Refill is performed in clean environment through the needle inserted in the 
reservoir port of the upper surface of the pump. Average inter refill period is 
three (1 – 6 ) months and after seven or eight years most programmable pump 
models must be reimplanted due to battery end of life. 
Nevertheless intrathecal baclofen therapy is connected with presumable costs, 
up-front costs of therapy can be expected to be reduced in: hospital bed days 
used in management of spasticity, number of orthopaedic procedures required, 
option of pressure sores/decubitus ulcers, oral treatment and orthoses and 
other aids (7, 10).
Complications After Baclofen Pump Implantation
Complications regarding treatment with intrathecal baclofen represents an 
overdose or withdrawal of the drug and peri/post-operative infections. Mistakes 
in programming or use of wrong solution concentration are major factors for 
overdose or withdrawal of the drug. Kinking or displacement of the catheter 
extradurally can be another reason for withdrawal of baclofen. Both conditions 
are potentially life threatening, so every patient must beside the symptomatic 
intervention undergo close observation, if needed, in the intensive care unit. 
Signs of baclofen overdose:
• Sudden and unexplained hypotonus 
• Narrow pupils (similar to opioid overdose) 
• Hypersalivation, nausea, vomiting
• “Empty head” feeling, sleepiness, vertigo. 
• Loss of consciousness 
• Breathing depression, apnea, coma.
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Signs of baclofen withdrawal:
• Sudden und unexplained raise of muscle tone 
• Generalised pruritus 
• Hyperthermia without inflammatory reason
• Tremor 
• Headache 
• Disorientation and hallucinations 
• Vegetative autonomic dystonia in patients after spinal cord injury 
• Rhabdomyolysis 
• Acute renal failure, DIC, hypoxic brain injury, death
Infection of the pump system (pump or catheter) is a serious complication, 
because it represents an indirect threat of a central nervous system infection. 
Complications of an untreated pump infection are fulminant meningitis and 
ventriculitis. Therefore, the recommended decision after declaring presence 
of pathogenic bacteria on the material is immediate explantation of the pump 
and catheter with prolonged antibiotic treatment with an infection disease 
specialist follow up.
Presentation of Population
Altogether 97 patients with baclofen or morphine intrathecal delivery pump 
have been treated for intractable spasticity in Slovenia since 2001. 
From the current population of 77 patients, there are 72 patients receiving 
baclofen only, two patients receiving an polyanalgetic mixture of morphine, 
clonidine and baclofen and three patients receiving morphine only with an 
intrathecal delivery pump. 
The average age in the current population is 42.6 yrs (12-71). The leading 
pathology in the population is spinal cord injury / vertebral disease (26/77), 
followed by acquired brain injury (16/77), multiple sclerosis (16/77), cerebral 
palsy (13/77), cerebrovascular disease (2/77), moto-neuron disease (2/77) 
and one patient with Hereditary spastic paraparesis and with Stiff person 
syndrome. Eight patients died since the beginning of the programme and no 
death was connected with the ITB pump treatment. In five cases a definitive 
pump explantation was decided, due to sepsis (2/5), skin perforation (2/5) and 
discontinued need for therapy (1/5).
The average dose of the daily baclofen is 355 micrograms (55 – 1.750) and 
the average intrathecal dose of daily morphine in five pain patients is 9,8 mg.
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The average pump inter-refill period in spastic and pain patients is 135 days, 
which on average means three refill sessions per patient per year.
Conclusion
Intrathecal baclofen therapy for spasticity is invasive, life-long, with possible 
life threatening complications. The selection procedure is therefore the most 
important part of the ITB treatment process. Benefits of therapy reveal the 
negative option. An informed and carefully selected patient at the right time 
and with reasonably defined treatment goals will match favourable results with 
satisfied patients and caregivers
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